Intellia Therapeutics has Regeneron in its corner. (Marcos Silva/iStock/Getty Images Plus)

Intellia Therapeutics has received the green light to study its in vivo CRISPR-based gene editing therapy in the U.S., positioning it to start a phase 3 trial of the Regeneron-partnered candidate by the end of the year.

Massachusetts-based Intellia worked with sites in Europe and New Zealand to study the drug candidate, NTLA-2001, in a phase 1 trial. Having shown the candidate may safely reduce levels of misfolded TTR, a protein that drives the rare, life-threatening disease ATTR amyloidosis, the biotech has secured the FDA’s blessing to include U.S. sites in an upcoming phase 3 trial.

Intellia is aiming to start the global phase 3 trial by the end of the year, keeping it on track to achieve the timeline it set out in August. In a statement, Intellia CEO John Leonard, M.D., said the planned study will mark “the first in vivo CRISPR-based candidate to begin late-stage clinical development.” Editas Medicine paused its lead in vivo candidate, EDIT-101, after reporting phase 1/2 data 11 months ago.

The statement about the FDA clearance lacks details of the design of the NTLA-2001 phase 3 trial. David Lebwohl, M.D., chief medical officer at Intellia, gave investors a rough idea of what to expect on a conference call in August, explaining that it will be a “pretty similar” size to Alnylam’s HELIOS-B study.

Alnylam has enrolled 655 ATTR amyloidosis patients in HELIOS-B, a placebo-controlled phase 3 trial that is designed to validate vutrisiran in the indication. The RNAi therapeutic is one of several molecules that are in development or approved for use in ATTR amyloidosis.

BridgeBio Pharma shared phase 3 data on its candidate, acoramidis, earlier this year, while Ionis Pharmaceuticals, Pfizer and other companies are also active in the space.

Intellia has Regeneron in its corner. Under the terms of the partnership, Intellia is taking the lead on the development and commercialization of NTLA-2001, and Regeneron is covering around 25% of the costs in return for the same share of the profits.


Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.

Related News

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.